Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Highlights•Dose selection for new combination therapy in tuberculosis has remained
empirical.•Novel tools are needed for effective translation of preclinical models to humans.•A …

Application of clinical pharmacology best practices is essential to the efficient and rational
development of drugs. In general, knowledge gained about exposure–response …

To tackle the global TB epidemic effectively, novel treatment strategies are critically needed
to shorten the duration of TB therapy and treat drug-resistant TB. Drug development for TB …

Background The sites of mycobacterial infection in the lungs of tuberculosis (TB) patients
have complex structures and poor vascularization, which obstructs drug distribution to these …

Standard treatment for active tuberculosis (TB) requires drug treatment with at least four
drugs over six months. Shorter-duration therapy would mean less need for strict adherence …

Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis.
However, we lack well-validated, high-throughput in vitro models that predict animal …

Tuberculosis (TB) is the deadliest infectious disease worldwide. The design of new
treatments for TB is hindered by the large number of candidate drugs, drug combinations …

Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …